Browsing ICR Divisions by author "Brown, Robert"
Now showing items 1-12 of 12
-
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
Glasspool, RM; Brown, R; Gore, ME; Rustin, GJS; McNeish, IA; et al. (NATURE PUBLISHING GROUP, 2014-04-15)BACKGROUND: Our previous laboratory and clinical data suggested that one mechanism underlying the development of platinum resistance in ovarian cancer is the acquisition of DNA methylation. We therefore tested the hypothesis ... -
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Tutt, A; Tovey, H; Cheang, MCU; Kernaghan, S; Kilburn, L; et al. (NATURE PUBLISHING GROUP, 2018-04-30)Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs ... -
Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance.
Gallon, J; Loomis, E; Curry, E; Martin, N; Brody, L; et al. (BMC, 2021-06-05)BACKGROUND: Resistance to DNA damaging chemotherapies leads to cancer treatment failure and poor patient prognosis. We investigated how genomic distribution of accessible chromatin sites is altered during acquisition of ... -
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
Talhouk, A; George, J; Wang, C; Budden, T; Tan, TZ; et al. (AMER ASSOC CANCER RESEARCH, 2020-10-15)PURPOSE: Gene expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, ... -
Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells.
Curry, E; Green, I; Chapman-Rothe, N; Shamsaei, E; Kandil, S; et al. (BMC, 2015-08-21)BACKGROUND: Many cancers show aberrant silencing of gene expression and overexpression of histone methyltransferases. The histone methyltransferases (HKMT) EZH2 and EHMT2 maintain the repressive chromatin histone methylation ... -
Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis.
Curry, E; Zeller, C; Masrour, N; Patten, DK; Gallon, J; et al. (AMER ASSOC CANCER RESEARCH, 2018-03-15)Bivalent chromatin domains containing both active H3K4me3 and repressive H3K27me3 histone marks define gene sets poised for expression or silencing in differentiating embryonic stem (ES) cells. In cancer cells, aberrantly ... -
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer.
Brunton, H; Caligiuri, G; Cunningham, R; Upstill-Goddard, R; Bailey, U-M; et al. (CELL PRESS, 2020-05-12)Pancreatic ductal adenocarcinoma (PDAC) can be divided into transcriptomic subtypes with two broad lineages referred to as classical (pancreatic) and squamous. We find that these two subtypes are driven by distinct metabolic ... -
International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis.
Scott, AJ; Alexander, JL; Merrifield, CA; Cunningham, D; Jobin, C; et al. (BMJ PUBLISHING GROUP, 2019-09-01)OBJECTIVE: In this consensus statement, an international panel of experts deliver their opinions on key questions regarding the contribution of the human microbiome to carcinogenesis. DESIGN: International experts in ... -
Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Flower, KJ; Ghaem-Maghami, S; Brown, R (BENTHAM SCIENCE PUBL LTD, 2018-01-01)The efficacy of cancer immunotherapy relies on the ability of the host immune system to recognise the cancer as non-self and eliminate it from the body. Whilst this is an extremely fertile area of medical research, with ... -
Prognostic gene expression signature for high-grade serous ovarian cancer.
Millstein, J; Budden, T; Goode, EL; Anglesio, MS; Talhouk, A; et al. (ELSEVIER, 2020-09-01)BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated ... -
The surgical intelligent knife distinguishes normal, borderline and malignant gynaecological tissues using rapid evaporative ionisation mass spectrometry (REIMS).
Phelps, DL; Balog, J; Gildea, LF; Bodai, Z; Savage, A; et al. (NATURE PUBLISHING GROUP, 2018-05-01)BACKGROUND: Survival from ovarian cancer (OC) is improved with surgery, but surgery can be complex and tumour identification, especially for borderline ovarian tumours (BOT), is challenging. The Rapid Evaporative Ionisation ... -
Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression.
Natoli, M; Gallon, J; Lu, H; Amgheib, A; Pinato, DJ; et al. (BMJ PUBLISHING GROUP, 2021-01-01)BACKGROUND: Endogenous retroviruses (ERVs) play a role in a variety of biological processes, including embryogenesis and cancer. DNA methyltransferase inhibitors (DNMTi)-induced ERV expression triggers interferon responses ...